Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | LYN | P07948 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
| ▸ | FLT4 | P35916 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | BLK | P51451 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165165 | 0.92 | TRPV1 (0.46) | TRPV1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL167970 | 0.89 | RIPK1 (0.47) | KDRBRAFRIPK1ABL1LCK | |
| SCHEMBL166850 | 0.89 | KMT2A (0.42) | TRPV1GSK3BGSK3AKDRBRAF | |
| SCHEMBL168670 | 0.89 | MAPT (0.40) | TRPV1KDRMEN1KMT2A | |
| SCHEMBL165118 | 0.88 | NAMPT (0.44) | KDRBRAFFLT1FLT3CDK8 | |
| SCHEMBL169174 | 0.87 | KDR (0.43) | TRPV1KDRFLT3PTGER3EPHB4 | |
| SCHEMBL167218 | 0.87 | TRPV1 (0.42) | TRPV1KDRLCKLYNFLT1 | |
| SCHEMBL167322 | 0.87 | KDM4E (0.44) | TRPV1KDRRIPK1LCKFLT1 | |
| SCHEMBL166695 | 0.87 | MEN1 (0.46) | TRPV1KDRPTGER3EPHB4MEN1 | |
| SCHEMBL167503 | 0.86 | KDR (0.46) | GSK3BGSK3AKDRBRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| EP-2611806-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Ascepion Pharmaceuticals, Inc. (CN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | TRPV1 4297/4885GSK3B 203/4885GSK3A 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.